These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30685913)

  • 1. Wells' Syndrome Induced by Ustekinumab.
    Rozenblat M; Cohen-Barak E; Dodiuk-Gad R; Ziv M
    Isr Med Assoc J; 2019 Jan; 21(1):65. PubMed ID: 30685913
    [No Abstract]   [Full Text] [Related]  

  • 2. Case of recurrent severe cellulitis and cutaneous candidiasis during psoriasis treatment with ustekinumab.
    Miyachi H; Nakamura Y; Wakabayashi S; Iwasawa MT; Oikawa A; Watanabe A; Matsue H
    J Dermatol; 2017 Aug; 44(8):e206-e207. PubMed ID: 28432713
    [No Abstract]   [Full Text] [Related]  

  • 3. Psoriasis vulgaris complicated by eosinophilic pneumonia during ustekinumab treatment.
    Yashiro M; Maejima H; Taniguchi T; Katsuoka K; Kimura M; Wada M
    Eur J Dermatol; 2013; 23(3):396-7. PubMed ID: 23728153
    [No Abstract]   [Full Text] [Related]  

  • 4. Worsening of Psoriatic Arthritis After Ustekinumab Treatment.
    Onsun N; Yalcin B; Sallahoglu K; Rezvani A
    Am J Ther; 2018; 25(3):e381-e382. PubMed ID: 29189317
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of ustekinumab in severe psoriasis with chronic hepatitis B.
    Raymundo AR; Facin AP; Silva de Castro CC; Faria AR
    Indian J Dermatol Venereol Leprol; 2016; 82(3):326-8. PubMed ID: 27088944
    [No Abstract]   [Full Text] [Related]  

  • 6. Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.
    Čarija A; Ivić I; Marasović-Krstulović D; Puizina-Ivić N
    Rheumatology (Oxford); 2015 Nov; 54(11):2114-6. PubMed ID: 26242857
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period.
    Megna M; Napolitano M; Balato N; Monfrecola G; Villani A; Ayala F; Balato A
    Clin Exp Dermatol; 2016 Jul; 41(5):564-6. PubMed ID: 27028505
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of ustekinumab for the treatment of psoriasis vulgaris with myotonic dystrophy.
    Fujita Y; Shinkuma S; Nomura T; Shimizu H
    Eur J Dermatol; 2016 Apr; 26(2):187-8. PubMed ID: 26643260
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab.
    MacArthur KM; Merkel PA; Van Voorhees AS; Nguyen J; Rosenbach M
    J Drugs Dermatol; 2016 Mar; 15(3):359-62. PubMed ID: 26954323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life of lesions in eosinophilic cellulitis (Wells' syndrome)-a condition that may be missed at first sight.
    Peckruhn M; Tittelbach J; Schliemann S; Elsner P
    Am J Dermatopathol; 2015 Feb; 37(2):e15-7. PubMed ID: 25238447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
    Fioranelli M; Roccia MG; Lotti T
    Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
    [No Abstract]   [Full Text] [Related]  

  • 12. Wells' syndrome presenting as a noninfectious bullous cellulitis in a child.
    Shams M; Hudgens J; Lesher JL; Florentino F
    Pediatr Dermatol; 2012; 29(2):224-6. PubMed ID: 22409475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial hypertension syndrome in a patient with psoriasis receiving ustekinumab.
    Reyes Bueno JA; Reyes Garrido V; León A; Bustamante R
    Neurologia (Engl Ed); 2019 May; 34(4):281-282. PubMed ID: 28712842
    [No Abstract]   [Full Text] [Related]  

  • 14. Eosinophilic cellulitis presented with semicircular pattern.
    Karabudak O; Dogan B; Taskapan O; Harmanyeri Y
    J Dermatol; 2006 Nov; 33(11):798-801. PubMed ID: 17073997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy.
    Lis-Święty A; Skrzypek-Salamon A; Arasiewicz H; Brzezińska-Wcisło L
    Allergol Int; 2015 Oct; 64(4):382-3. PubMed ID: 26433537
    [No Abstract]   [Full Text] [Related]  

  • 16. [Eosinophilic cellulitis (Wells syndrome)].
    Plötz SG; Abeck D; Behrendt H; Simon HU; Ring J
    Hautarzt; 2000 Mar; 51(3):182-6. PubMed ID: 10789080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug-induced interstitial lung disease (DILD) during treatment with ustekinumab].
    Sorger C; Simon JC; Treudler R
    Hautarzt; 2020 Apr; 71(4):309-312. PubMed ID: 31792580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.
    Membrillo de Novales FJ; Ávila Jiménez A; Merino Meléndez L; Torres León J; López Soberón E; Fe Marqués A; Pérez Mochales JF
    J Clin Rheumatol; 2015 Apr; 21(3):171-3. PubMed ID: 25807103
    [No Abstract]   [Full Text] [Related]  

  • 19. Wells' Syndrome Associated with Coxsackievirus A6 Infection.
    Yoshii Y; Ishikawa T; Munetsugu T; Nishizawa A; Fujimoto N; Satoh T
    Acta Derm Venereol; 2018 Aug; 98(8):791-792. PubMed ID: 29972218
    [No Abstract]   [Full Text] [Related]  

  • 20. An analysis of Drug Survival, Effectiveness, and Safety in Moderate to Severe Psoriasis Treated With Ustekinumab: An Observational Study of 69 Patients in Routine Clinical Practice.
    Salgüero Fernández I; Gil MH; Sanz MS; Gullón GR
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):244-246. PubMed ID: 29961546
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.